Global Transcatheter Pulmonary Valve Market Report and Forecast 2023-2031

The global transcatheter pulmonary valve market size attained a value of USD 80.2 million in 2022. The market is expected to grow at a CAGR of 5.8% during the forecast period of 2023-2031 to attain a value of USD 133.2 million by 2031.

Transcatheter Pulmonary Valve Market: Introduction

Transcatheter pulmonary valve (TPV) refers to a medical device and procedure used to treat certain heart conditions involving the pulmonary valve. The pulmonary valve is responsible for regulating blood flow from the right ventricle of the heart to the pulmonary artery, which carries blood to the lungs for oxygenation.

In cases where the pulmonary valve is damaged, dysfunctional, or absent, a TPV can be employed as a less invasive alternative to open-heart surgery. The TPV is designed to replace or repair the pulmonary valve without the need for traditional surgery.

The TPV procedure involves the insertion of a specially designed catheter into a blood vessel, typically in the groin area, which is then threaded through the blood vessels to the heart. The catheter carries the replacement valve, which is typically made of biocompatible materials, such as bovine or porcine tissue or a synthetic valve.

Once in position, the TPV is expanded using various techniques, such as balloon inflation, self-expanding mechanisms, or a combination of both, allowing it to effectively regulate blood flow through the pulmonary valve. This improves the functioning of the heart and enhances blood oxygenation by enabling proper blood flow to the lungs.

The use of TPV offers several benefits over traditional open-heart surgery, including:

• Minimally invasive: The TPV procedure requires only a small incision or puncture in the groin area, significantly reducing the invasiveness of the treatment. This leads to shorter recovery times, decreased pain, and potentially fewer complications compared to open-heart surgery
• Avoidance of cardiopulmonary bypass: TPV can often be performed without the need for a heart-lung machine, which is typically required during open-heart surgery. This avoids the associated risks and complexities of placing the patient on bypass, further improving the safety profile of the procedure
• Reduced hospitalization: Patients who undergo TPV often experience shorter hospital stays compared to those who undergo open-heart surgery. This allows for a quicker return to normal activities and a faster overall recovery
• Reproducible and expandable: TPV devices are designed to be expandable, meaning they can accommodate the growth of the patient, particularly in paediatric cases. Additionally, if future valve replacements are necessary, the TPV procedure can be repeated or updated without the need for repeat open-heart surgeries
• Transcatheter pulmonary valve replacement has proven to be a valuable alternative for patients with pulmonary valve disorders, offering improved outcomes and quality of life while minimizing the invasiveness and risks associated with traditional surgical interventions. However, the suitability of TPV depends on individual patient factors and should be assessed by a qualified healthcare professional. Market Division Based on Prevalence, Age, Gender, and Lifestyle Habits

Transcatheter Pulmonary Valve Market Segmentations

The market can be categorised into technology, application, and region.

Market Breakup by Technology

• Balloon-Expanded Transcatheter Valve
• Self-Expanded Transcatheter Valve

Market Breakup by Application

• Pulmonary Stenosis
• Pulmonary Regurgitation
• Pulmonary Atresia
• Others

Transcatheter Pulmonary Valve Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Transcatheter Pulmonary Valve Market Scenario

The market has witnessed significant growth and advancements in recent years. Transcatheter pulmonary valve replacement (TPVR) is a minimally invasive procedure that allows for the replacement of a dysfunctional pulmonary valve using a transcatheter approach, eliminating the need for open-heart surgery. This procedure offers numerous benefits, including reduced hospital stays, faster recovery times, and fewer complications compared to traditional surgical interventions.

The market for transcatheter pulmonary valves is being driven by several factors. Firstly, there is a growing incidence of congenital heart diseases, including pulmonary valve stenosis and regurgitation, which necessitate the need for valve replacement. Additionally, the rising preference for minimally invasive procedures among both patients and physicians is boosting the demand for transcatheter interventions.

Technological advancements in transcatheter valve technologies have also contributed to market growth. The development of innovative valve designs, such as self-expanding valves and balloon-expandable valves, has improved procedural outcomes and expanded the patient pool eligible for TPVR. Furthermore, the introduction of advanced imaging techniques and navigation systems has enhanced the accuracy and safety of the procedure.

Geographically, the market for transcatheter pulmonary valves is witnessing steady growth across multiple regions, including North America, Europe, Asia Pacific, and the rest of the world. Developed regions, such as North America and Europe, have well-established healthcare infrastructure and favourable reimbursement policies, driving the adoption of TPVR. In contrast, the Asia Pacific region is experiencing rapid market growth due to increasing healthcare expenditure, improving accessibility to advanced cardiac care, and rising awareness about minimally invasive treatment options.

However, challenges exist in the transcatheter pulmonary valve market. The high cost of transcatheter valve devices and the limited availability of skilled healthcare professionals proficient in performing TPVR procedures can hinder market growth, especially in emerging economies. Moreover, stringent regulatory requirements for device approval and reimbursement can pose barriers for market players.

Nevertheless, with ongoing research and development activities, coupled with increasing investments by key market players, the transcatheter pulmonary valve market is expected to witness continued growth in the coming years. The development of novel valve technologies, expanding indications for TPVR, and efforts to improve patient outcomes will likely drive market expansion and offer new opportunities for both manufacturers and patients in need of pulmonary valve replacement.

Key Players in the Global Transcatheter Pulmonary Valve Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the transcatheter pulmonary valve market are as follows:

• Boston Scientific Corporation
• Braile Biomedica
• Artivion, Inc
• Edwards Lifesciences Corporation
• JenaValve Technology, Inc
• LivaNova PLC
• Medtronic
• Venus Medtech
• Lepu Medical Technology
• Jude Medical Inc